Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. - Wikidata - wikimedia - TriplyDB

Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice.

Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice.

http://www.wikidata.org/entity/Q39649085

about

Annexin A1 and the Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and Clearance Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 1: Compositions and Features Wound repair: role of immune-epithelial interactions Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/- Mice on Western Type Diet The restorative role of annexin A1 at the blood-brain barrier.Immune cell screening of a nanoparticle library improves atherosclerosis therapy Inflammation-a Critical Appreciation of the Role of Myeloid Cells Shifting the Focus of Preclinical, Murine Atherosclerosis Studies From Prevention to Late-Stage Intervention.Recent insights into the cellular biology of atherosclerosis Atherosclerosis and Nanotechnology: Diagnostic and Therapeutic Applications.Bioregulatory systems medicine: an innovative approach to integrating the science of molecular networks, inflammation, and systems biology with the patient's autoregulatory capacity?Towards programming immune tolerance through geometric manipulation of phosphatidylserine.Macrophage Apoptosis and Efferocytosis in the Pathogenesis of Atherosclerosis Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.The Role of Efferocytosis in Atherosclerosis.Cytokines: roles in atherosclerosis disease progression and potential therapeutic targets Micro-RNAs and macrophage diversity in atherosclerosis: new players, new challenges…new opportunities for therapeutic intervention?Annexin A1 in blood mononuclear cells from patients with coronary artery disease: Its association with inflammatory status and glucocorticoid sensitivity.Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles.Macrophage Phenotype and Function in Different Stages of Atherosclerosis.Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis.Targeting and therapeutic peptides in nanomedicine for atherosclerosis.An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.Inflammation and plaque vulnerability.Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis.Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology.Applying nanomedicine in maladaptive inflammation and angiogenesis.Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.Delivery strategies to control inflammatory response: Modulating M1-M2 polarization in tissue engineering applications.Inflammatory processes in cardiovascular disease: a route to targeted therapies.Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis.Annexin A1: shifting the balance towards resolution and repair.E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis.Bolstering cholesteryl ester hydrolysis in liver: A hepatocyte-targeting gene delivery strategy for potential alleviation of atherosclerosis.Alpha-2-macroglobulin loaded microcapsules enhance human leukocyte functions and innate immune response.Local Inhibition of Macrophage and Smooth Muscle Cell Proliferation to Suppress Plaque Progression.The advantageous role of annexin A1 in cardiovascular disease.Smart Radiation Therapy Biomaterials.The walking dead: macrophage inflammation and death in atherosclerosis.

P2860

Q26765186-52B1A217-EA23-4644-8984-DD03AFBABB2B Q26798426-C631E70C-9B8B-47E5-BC81-3DF1D371858E Q26801818-D38E7201-8259-4421-BC8D-66706684F24B Q27303970-96DE3CD8-763B-4E53-8405-5534658D304B Q27687514-C3E28CEC-EE7C-42C8-869A-69D867C4A42D Q28393434-DC10E69A-9BEB-4142-9604-1D97B7724034 Q28595434-819C4DF7-F0D3-47AB-B92E-D6D18E45AF9F Q30253052-1A9CBAF0-4731-4060-B914-C5B70C07CD1C Q30300194-753592A5-0D2F-4B9E-B14F-08BE9B607798 Q30364399-C3E05FFE-CE55-4BA0-AE57-8322C39EC87D Q30661665-2FE4D34B-0C92-45AC-A264-7152268018C0 Q30751004-5C0DEFB5-FE6D-480C-8D55-6D38F7EA8526 Q33764821-43D1FA55-6E54-40BB-87D7-F4473EECFE9B Q33856678-67CAA680-034F-4331-B50C-B8DF897605AA Q33902253-B5D5233A-65CD-4050-93D6-C777A042BF2E Q34680660-F5632E52-6AD7-4FFF-A491-063CF68E1BF4 Q36064353-9C317B78-CF11-41E6-A0EB-0B3C455D7877 Q36125865-7405585D-DA39-48A3-82EE-E4393A66ED03 Q36318569-AF0256CA-758B-467D-B4F7-70F85E358AFB Q36396054-1C009E38-8520-4C50-81A7-E83757265C55 Q36602809-381F34B8-BC63-4656-ACE5-8BD57981312A Q36848196-D38229DF-031A-44D1-8223-0CBF8A29D914 Q36913594-B07AED07-6CD1-43EF-A4F0-A89593BA7BF4 Q37282266-5F81B25C-A49F-4244-81FF-7CFD6CCE3F9D Q37370224-793EF22C-35C8-4174-8385-4BC553C23B9C Q37544674-9427FF92-A641-4EA4-B38D-5358B7370C7B Q37603197-F5B20E70-ADF4-4A5B-987B-1A6F9FA2AA21 Q38557650-DF9B2337-6851-4EDB-A747-B11A40740A4A Q38681468-0D66B22D-8EB7-471B-9A3A-0166A4B03FD2 Q38700498-409EBD5F-995E-44A0-A832-77D7AB109CE4 Q38788685-8FC4B79F-71D8-4985-8C6D-C8B6ABEAB18F Q38828033-8E1E74C5-BEDF-4F43-BB8C-B98110EFC5B3 Q38846007-891B9779-B71F-4905-91D6-26490BCF9058 Q38858690-D6CF9F27-325B-4FC4-AB63-BCFAC27BA260 Q38871582-2FD79EAF-3862-4681-8D5B-07BD447AE6AF Q38962381-BDBB3BCC-02A3-4A30-BE8F-CBFBF48A1119 Q39003364-D44F65BC-1EE0-4B16-BFE8-CB5EDEF3ACC1 Q39012576-79C51844-7576-4384-85B4-7AADAB765F81 Q39105322-5479BA56-EFF0-4476-98B1-4207D4A3A3C8 Q39109119-6BA85A1A-6C63-4095-8C91-B6D56D43E7F1

P2860

Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice.

http://www.wikidata.org/entity/Q39649085

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Targeted nanoparticles contain ...... in hypercholesterolemic mice.

@en

Targeted nanoparticles contain ...... in hypercholesterolemic mice.

@nl

type

label

Targeted nanoparticles contain ...... in hypercholesterolemic mice.

@en

Targeted nanoparticles contain ...... in hypercholesterolemic mice.

@nl

prefLabel

Targeted nanoparticles contain ...... in hypercholesterolemic mice.

@en

Targeted nanoparticles contain ...... in hypercholesterolemic mice.

@nl

P1433

Q39649085-88965537-2CD4-4166-AB43-84776E935BA9

P1476

Q39649085-894DA241-B775-4859-9FDB-0C6C48D22AAA

P2093

Q39649085-0C9B4BB1-A9DB-4C0E-AFA6-B3C3683607BD

Q39649085-34D9DCED-F4FB-4880-ADAA-EADD790FD23E

Q39649085-4FE3978A-3A0A-4A81-9DAD-8A8A84D9F732

Q39649085-5FA605A2-F307-4894-9F4B-F7A48435FBA0

Q39649085-619CFA9C-8A98-42D9-81A8-6BEE601453B4

Q39649085-7A6D7154-55D7-4767-ADEF-25206A96BCE9

Q39649085-7F6E17D0-D9EF-4848-9B47-F3AAD4F58C8C

Q39649085-945DD6E4-E56F-4BB6-B7CB-9BB731AECA90

Q39649085-DE79B47D-02C0-46DC-B1ED-89061A31E7F9

P2860

Q39649085-05709082-CD86-4AFD-8BD1-63FBEC6B627C

Q39649085-07FD7EEC-C93F-4E4A-87D3-2E793AA953D8

Q39649085-088F2D77-32FA-400F-9602-6D1894CAFF1B

Q39649085-0DDCEAF4-6124-4318-8986-0FA8FEFF06D1

Q39649085-13B411A8-5EFF-460D-B08E-CB94CBE0ED26

Q39649085-188F544E-D913-48B2-9C87-A6C47B777D5F

Q39649085-20E15A0A-47FA-4B72-B0EE-8DFF6418A7F6

Q39649085-28A383A7-9C2E-4397-B997-9E9DC272BB1B

Q39649085-30CF42E3-FBE2-45BD-9309-A04D090D0194

Q39649085-338D9FC0-C89A-4A92-9B9A-38C1D8DA443C

P304

Q39649085-1FE6FF47-8CAA-487B-A683-E183CA56A6B4

P31

Q39649085-465B3C32-BEEE-4EDC-8D1D-E5D3E49D4FF1

P356

Q39649085-4B9F37F7-FB9C-498B-BC57-16BE7F359BA8

P407

Q39649085-9DEFD4C9-502A-499E-ACBB-42C3DD9D41CB

P433

Q39649085-F57168F2-8A26-4997-943F-4CB055D7EFD0

P478

Q39649085-2BCBA760-0C1B-4AF0-9328-9473FB651237

P50

Q39649085-93BFB4C4-46B5-4852-9AC2-7F814E5C0A84

P577

Q39649085-D0C87A47-4762-4E8B-896B-02171F536687

P698

Q39649085-EEBF809E-BBB5-410C-A0CA-9061E9B2BABA

P921

Q39649085-17EE39FD-53B1-4801-9994-F69D49C5689B

Q39649085-62C5067D-FF4C-4E52-9427-CCBD298D27F7

Q39649085-AD37CC1E-EDA0-4098-80B6-B2A211002226

P932

Q39649085-0981C4FC-0648-45F0-BF90-74C8842431C8

P356

SCITRANSLMED.AAA1065

P1433

Science Translational Medicine

P1476

Targeted nanoparticles contain ...... in hypercholesterolemic mice.

@en

P2093

Devram Ghorpade

http://www.w3.org/2001/XMLSchema#string

Gabrielle Fredman

http://www.w3.org/2001/XMLSchema#string

George Kuriakose

http://www.w3.org/2001/XMLSchema#string

Ira Tabas

http://www.w3.org/2001/XMLSchema#string

Jaclyn Milton

http://www.w3.org/2001/XMLSchema#string

Mauro Perretti

http://www.w3.org/2001/XMLSchema#string

Omid Farokzhad

http://www.w3.org/2001/XMLSchema#string

Raymond Chiasson

http://www.w3.org/2001/XMLSchema#string

Stefano Spolitu

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-10: new perspectives on an old cytokine

Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke)

Anti-inflammatory therapy in chronic disease: challenges and opportunities

Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor

RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis

Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation

Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications

Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions

Resolvin D1 binds human phagocytes with evidence for proresolving receptors

Annexin A1 and glucocorticoids as effectors of the resolution of inflammation

P304

275ra20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAA1065

http://www.w3.org/2001/XMLSchema#string

P407

P433

275

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25695999

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

hypercholesterolemia

P932

4397585

http://www.w3.org/2001/XMLSchema#string